Literature DB >> 11139190

Naturally acquired antibody responses to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in Korea.

J W Park1, S H Moon, J S Yeom, K J Lim, M J Sohn, W C Jung, Y J Cho, K W Jeon, W Ju, C S Ki, M D Oh, K Choe.   

Abstract

We expressed a protein in Saccharomyces cerevisiae in order to evaluate the humoral immune responses to the C-terminal region of the merozoite surface protein 1 of Plasmodium vivax. This protein (Pv200(18)) had a molecular mass of 18 kDa and was reactive with the sera of individuals with patent vivax malaria on immunoblotting analysis. The levels of immunoglobulin M (IgM) and IgG antibodies against Pv200(18) were measured in 421 patients with vivax malaria (patient group), 528 healthy individuals from areas of nonendemicity (control group 1), and 470 healthy individuals from areas of endemicity (control group 2), using the indirect enzyme-linked immunosorbent assay (ELISA) method. To study the longevity of the antibodies, 20 subjects from the patient group were also tested for the antibody levels once a month for 1 year. When the cutoff values for seropositivity were determined as the mean + 3 x standard deviation of the antibody levels in control group 1, both IgG and IgM antibody levels were negative in 98.5% (465 of 472) of control group 2. The IgG and IgM antibodies were positive in 88.1% (371 of 421) and 94.5% (398 of 421) of the patient group, respectively. The IgM antibody became negative 2 to 4 months after the onset of symptoms, whereas the IgG antibody usually remained positive for more than 5 months. In conclusion, indirect ELISA using Pv200(18) expressed in S. cerevisiae may be a useful diagnostic method for vivax malaria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11139190      PMCID: PMC96005          DOI: 10.1128/CDLI.8.1.14-20.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  31 in total

1.  Long-lasting protective immunity against rodent malaria parasite infection at the blood stage by recombinant BCG secreting merozoite surface protein-1.

Authors:  S Matsumoto; H Yukitake; H Kanbara; T Yamada
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

2.  A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth.

Authors:  S P Chang; H L Gibson; C T Lee-Ng; P J Barr; G S Hui
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

3.  Prevalence of antibody to heterologous circumsporozoite protein of Plasmodium vivax in Thailand.

Authors:  R A Wirtz; R Rosenberg; J Sattabongkot; H K Webster
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

Review 4.  The precursor to major merozoite surface antigens: structure and role in immunity.

Authors:  A A Holder
Journal:  Prog Allergy       Date:  1988

5.  Reemergence of Plasmodium vivax malaria in the republic of Korea.

Authors:  B H Feighner; S I Pak; W L Novakoski; L L Kelsey; D Strickman
Journal:  Emerg Infect Dis       Date:  1998 Apr-Jun       Impact factor: 6.883

6.  Plasmodium vivax: Merozoites, invasion of reticulocytes and considerations for malaria vaccine development.

Authors:  M R Galinski; J W Barnwell
Journal:  Parasitol Today       Date:  1996-01

7.  Antibody response to the circumsporozoite protein of Plasmodium vivax in naturally infected humans.

Authors:  E D Franke; C M Lucas; G Chauca; R A Wirtz; S Hinostroza
Journal:  Am J Trop Med Hyg       Date:  1992-03       Impact factor: 2.345

8.  Longitudinal study of naturally acquired humoral immune responses against the merozoite surface protein 1 of Plasmodium vivax in patients from Rondonia, Brazil.

Authors:  F Mertens; G Levitus; L M Camargo; M U Ferreira; A P Dutra; H A Del Portillo
Journal:  Am J Trop Med Hyg       Date:  1993-09       Impact factor: 2.345

9.  Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae.

Authors:  D C Kaslow; G Hui; S Kumar
Journal:  Mol Biochem Parasitol       Date:  1994-02       Impact factor: 1.759

10.  Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains.

Authors:  M J Blackman; I T Ling; S C Nicholls; A A Holder
Journal:  Mol Biochem Parasitol       Date:  1991-11       Impact factor: 1.759

View more
  16 in total

1.  Measurement of naturally acquired humoral immune responses against the C-terminal region of the Plasmodium vivax MSP1 protein using protein arrays.

Authors:  Jun-Hu Chen; Yue Wang; Kwon-Soo Ha; Feng Lu; In-Bum Suh; Chae Seung Lim; Jeong Hyun Park; Satoru Takeo; Takafumi Tsuboi; Eun-Taek Han
Journal:  Parasitol Res       Date:  2011-04-13       Impact factor: 2.289

2.  IgG isotype to C-terminal 19 kDa of Plasmodium vivax merozoite surface protein 1 among subjects with different levels of exposure to malaria in Brazil.

Authors:  Cristiane G Morais; Irene S Soares; Luzia H Carvalho; Cor Jesus F Fontes; Antoniana U Krettli; Erika Martins Braga
Journal:  Parasitol Res       Date:  2005-03-10       Impact factor: 2.289

3.  Duffy Blood Group System and the malaria adaptation process in humans.

Authors:  Gledson Barbosa de Carvalho; Glauber Barbosa de Carvalho
Journal:  Rev Bras Hematol Hemoter       Date:  2011

4.  Diagnosis of vivax malaria using an IgM capture ELISA is a sensitive method, even for low levels of parasitemia.

Authors:  Jae-Won Park; Seung Bum Yoo; Jae Hoon Oh; Joon-Sup Yeom; Young-Ha Lee; Young Yil Bahk; Yu Sam Kim; Kook Jin Lim
Journal:  Parasitol Res       Date:  2008-06-10       Impact factor: 2.289

5.  Humoral responses against the C-terminal region of merozoite surface protein 1 can be remembered for more than 30 years in persons exposed to Plasmodium vivax.

Authors:  Kook Jin Lim; Jea Won Park; Joon-Sup Yeom; Young-Ha Lee; Seung Bum Yoo; Jae Hoon Oh; Mi Jin Sohn; Young Yil Bahk; Yu Sam Kim
Journal:  Parasitol Res       Date:  2004-01-27       Impact factor: 2.289

6.  Genetic polymorphism and natural selection in the C-terminal 42 kDa region of merozoite surface protein-1 among Plasmodium vivax Korean isolates.

Authors:  Jung-Mi Kang; Hye-Lim Ju; Yoo-Mi Kang; Dong-Hyun Lee; Sung-Ung Moon; Woon-Mok Sohn; Jae-Won Park; Tong-Soo Kim; Byoung-Kuk Na
Journal:  Malar J       Date:  2012-06-18       Impact factor: 2.979

7.  Murine immune responses to a Plasmodium vivax-derived chimeric recombinant protein expressed in Brassica napus.

Authors:  Choonghee Lee; Hyung-Hwan Kim; Kyung Mi Choi; Kyung Won Chung; Yien Kyoung Choi; Mi Jung Jang; Tong-Soo Kim; Nam-Jun Chung; Ho-Gun Rhie; Ho-Sa Lee; Youngjoo Sohn; Hyuck Kim; Sung-Jae Lee; Hyeong-Woo Lee
Journal:  Malar J       Date:  2011-04-29       Impact factor: 2.979

8.  Serological detection of Plasmodium vivax malaria using recombinant proteins corresponding to the 19-kDa C-terminal region of the merozoite surface protein-1.

Authors:  Maria Helena C Rodrigues; Maristela G Cunha; Ricardo LD Machado; Orlando C Ferreira; Mauricio M Rodrigues; Irene S Soares
Journal:  Malar J       Date:  2003-11-14       Impact factor: 2.979

9.  Cellular and humoral immune responses against the Plasmodium vivax MSP-1₁₉ malaria vaccine candidate in individuals living in an endemic area in north-eastern Amazon region of Brazil.

Authors:  Evelyn K P Riccio; Paulo R R Totino; Lilian R Pratt-Riccio; Vitor Ennes-Vidal; Irene S Soares; Maurício Martins Rodrigues; José Maria de Souza; Cláudio Tadeu Daniel-Ribeiro; Maria de Fátima Ferreira-da-Cruz
Journal:  Malar J       Date:  2013-09-16       Impact factor: 2.979

10.  Naturally Acquired Antibody Responses to Plasmodium vivax and Plasmodium falciparum Merozoite Surface Protein 1 (MSP1) C-Terminal 19 kDa Domains in an Area of Unstable Malaria Transmission in Southeast Asia.

Authors:  Qinghui Wang; Zhenjun Zhao; Xuexing Zhang; Xuelian Li; Min Zhu; Peipei Li; Zhaoqing Yang; Ying Wang; Guiyun Yan; Hong Shang; Yaming Cao; Qi Fan; Liwang Cui
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.